MiMedx Group, Systagenix sales and marketing update

Systagenix launched Epifix in the U.S. to treat acute and chronic wounds. Systagenix has rights to the human amniotic allograft under a 2012 deal with MiMedx Group. Epifix is produced by MiMedx' Surg...